New Leadership at Newronika
Newronika is excited to introduce Keith Carlton as the new Executive Chairman, a pivotal appointment for the company as it advances in the rapidly evolving field of neuromodulation technology, particularly the adaptive deep brain stimulation system known as AlphaDBS™.
Strategic Growth and Experience
Keith Carlton brings with him a wealth of knowledge and experience from his successful career in the medical device industry. His leadership has consistently led to innovation and growth, attributes that Newronika values as it prepares to expand its reach globally.
Welcome from Leadership
Dr. Lorenzo Rossi, the Co-Founder and CEO, expressed enthusiasm about Carlton's appointment, emphasizing that his strategic vision is crucial for advancing AlphaDBS towards commercialization. "Keith's history of nurturing innovative technologies will play an essential role in enhancing treatment options for patients suffering from Parkinson's disease," he stated.
Community Confidence in Leadership
Carlo Sanfilippo, Senior Investment Manager at Indaco Venture Partners and board member, also welcomed Carlton, stating, "His experience and leadership will be instrumental as we navigate through the next phase of growth for the company." This confidence from invested members showcases the belief in Carlton's capabilities.
Transformative Potential of AlphaDBS
In his own words, Keith Carlton expressed excitement about joining Newronika at such a critical time. He highlighted the potential of the company's adaptive technology to set a new standard of care for neurological disorders. One of his immediate focuses will be to support the launch of an important Phase III pivotal trial in the U.S.
Recent Milestones and Future Directions
Newronika has achieved significant milestones recently, including receiving CE Mark approval for AlphaDBS, obtaining U.S. FDA IDE clearance, and successfully closing a €13.6 million Series B financing round. These accomplishments underline Newronika's commitment to transforming the landscape of neuromodulation therapy.
About Newronika
Newronika SpA stands as a beacon of innovation in deep brain stimulation technology. As a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, the company is dedicated to improving patient outcomes through real-time neurophysiological feedback. Based in Milan, Italy, Newronika is poised for expansion as it continues to secure regulatory approvals and launch clinical initiatives.
Contact Information
For further inquiries, Lorenzo Rossi, PhD, the Co-Founder and CEO, remains accessible for communication regarding Newronika's pioneering technologies and the upcoming trials. He is dedicated to advancing the company's mission in enhancing the lives of patients through innovative solutions.
Frequently Asked Questions
What is the role of Keith Carlton at Newronika?
Keith Carlton has been appointed as the Executive Chairman, bringing extensive experience in leading medical technology firms.
What is AlphaDBS?
AlphaDBS is Newronika's proprietary adaptive deep brain stimulation system designed to optimize therapy for patients with neurological disorders.
What recent milestones has Newronika achieved?
Newronika received CE Mark approval for AlphaDBS, achieved U.S. FDA IDE clearance, and closed a significant Series B financing round.
Who expressed confidence in Keith Carlton's appointment?
Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika, and Carlo Sanfilippo, Senior Investment Manager at Indaco Venture Partners, both voiced their support for Carlton.
Where is Newronika headquartered?
Newronika is headquartered in Milan, Italy, and is dedicated to advancing adaptive deep brain stimulation technology.
